Sanjula Jain, Ph.D., chief research officer at Trilliant Health spoke with Managed Healthcare Executive in this part two interview on recent research that revealed where telehealth use stands after the pandemic. While its use is declining, Jain advised what areas are of best focus for investment.
Hospitals face a number of challenges when it comes to deciding where to invest in telehealth services post-pandemic, according to Sanjula Jain, Ph.D., chief research officer at Trilliant Health.
Two areas hospitals should invest in or consider balancing is clinical utility with patient and provider preferences. Jain stressed the importance of distinguishing between cases where telehealth is effective and those where in-person care may be necessary.
"There are very few clinical use cases that really satisfy all those criteria and that kind of Venn diagram overlap," Jain said.
For example, within behavioral health, telehealth is well-suited for treating conditions such as anxiety and depression.
Related: Virtual Care's Role in Behavioral Health — Opportunities and Risks Highlighted Based on Recent Data
Physical exams are less critical and virtual visits may even enhance patient comfort. However, Jain cautioned that in other areas, such as primary care, the lack of physical exams or lab tests during virtual visits could compromise care quality.
Another area to look into is “payment parity.”
She shared that while telehealth might get reimbursed the same as in-person visits, the absence of extra services, such as lab tests during virtual appointments, can lower the overall payment for doctors.
Jain suggested thinking carefully about these issues before deciding to invest in telehealth.
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More